Pediatr. praxi. 2015;16(3):168-171

New options for treating oral candidiasis in children by using compounded medications

PharmDr.Zbyněk Sklenář, Ph.D., MBA1,2, MUDr.Vladimír Ščigel, Ph.D., MBA3, MVDr.Mgr.Kateřina Horáčková2,4
1 Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova v Praze
2 Fragnerova lékárna U Černého orla, Praha
3 Stomatologická klinika, 1. lékařská fakulta Univerzity Karlovy, Praha
4 Katedra analytické chemie, Farmaceutická fakulta UK, Hradec Králové

Oral candidiasis treatment in neonates and infants is still a current issue. Until recently, the therapeutic solution of this disease has been

consisting mainly in using extemporaneously prepared medicinal products in the oromucosal cavity containing non-specific antifungal

agents. Although oromucosal gels and suspensions containing specific antifungal agents are not available as registered products

in the Czech Republic, during the past five years got to enrichment of the portfolio for compounding with new substances. Nystatin

and miconazole are newly available for compounding and even they can be successfully used for the treatment of oromucosal candidiasis

in neonates, infants, children and adults. The paper aim is to inform physicians of treatment possibilities, oromucosal candidiasis

compounded preparations. The paper provides an overview of the available products. It focuses on the new substances - nystatin and

miconazole - and presents the current magistral formulas that can be used for the treatment of oromucosal candidiasis (thrush) and

that could thus completely replace the widely prescribed preparations with gentian (methyl) violet. Presented formulas were created by

the authors, who also checked in practice, the active substance for the extemporaneous preparation are currently available for routine

prescription and yet fully covered by public health insurance.

Keywords: candidiasis, neonates, magistral formulas, extemporaneous preparation, miconazole, nystatin, gentian (methyl) violet

Published: June 30, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sklenář Z, Ščigel V, Horáčková K. New options for treating oral candidiasis in children by using compounded medications. Pediatr. praxi. 2015;16(3):168-171.
Download citation

References

  1. Candida - oral - NICE CKC. Last revised in July 2013. Dostupné na území Velké Británie: http://cks.nice.org.uk/candida-oral
  2. Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clin Evid 2009; 18: 1304 (Online).
  3. Fadrhoncová A. Farmakoterapie kožních nemocí. 2. přeprac. a rozšíř. vyd. Praha: Grada Publishing 1999: 416 s.
  4. Sklenář Z, Ščigel V. Magistraliter receptura ve stomatologii. 1. vyd. Praha: Česká stomatologická komora v nakladatelství Havlíček Brain Team 2012: 343 s.
  5. Deutscher Arzneimittel-Codex (DAC) 2011/Neues Rezeptur-Formularium (NRF). Band I-III. Pharmazeutischen Laboratorium des NRF. Eschborn: Govi-Verlag und Stuttgart, Deutscher Apotheker-Verlag 2011.
  6. Český lékopis 2009, dopl. 2014. CD-ROM. el. verze. Praha: Grada Publishing, a. s., 2014.
  7. Dortová E, Dort J. Kožní a slizniční kandidóza u novorozence a kojence. Pediatr praxi 2012; 13 (3): 153-154.
  8. Čapková Š, Kohoutová V. Nebezpečí zevní léčby kožních onemocnění v dětském věku. Čs pediat. 1994; 49 (1): 38-43.
  9. Schillinger BM, Berstein M, Goldberg LA, Shalita AR. Boric acid poisoning. J Americ Academ Dermatol 1982: 7 (5): 667-673. Go to original source... Go to PubMed...
  10. McCourtie J, MacFarlane TW, Samaranayake LP. Effect of chlorhexidine gluconate on the Adherence of candida species to denture acrylic. J Med Microbiol 1985; 20:97-104. Go to original source... Go to PubMed...
  11. Wynn RL, Meiller TF, Crossley HL. Drug information handbook for dentistry. 16. ed., Lexi-Comp: Hudson 2010: 361-363.
  12. Sklenář Z. Riziková léčiva v pediatrické dermatologické magistraliter receptuře a jejich vhodné alternativy. Pediatr Praxi 2010; 11 (4): 232-235.
  13. Sklenář Z. Využití nystatinu v individuální přípravě léčivých přípravků v České republice. Farm. Obzor 2010; 79 (10): 203-206.
  14. Hašek J. Orofaryngeální kandidóza. Prakt lékáren 2015; 11 (1): 8-12.
  15. Hoppe JE, Hahn H. Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants. Antimycotics Study Group. Infection 1996; 24 (2): 136-139. Go to original source... Go to PubMed...
  16. Hoppe JE. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group. Pediatr Infect Dis J 1997; 16 (3): 288-293. Go to original source... Go to PubMed...
  17. Hašek J. Nové léčivé látky v magistraliter receptuře XIV - mikonazol a mikonazol-nitrát. Prakt lékáren. 2013; 9 (4-5): 192-195.




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.